Granulocyte macrophage colony stimulating factor

Jump to navigation Jump to search
Granulocyte macrophage colony stimulating factor
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC639H1006N168O196S8
Molar mass14434.5 g/mol
Colony stimulating factor 2 (granulocyte-macrophage)
PDB rendering based on 2gmf
Identifiers
Symbols CSF2 ; GMCSF; MGC131935; MGC138897
External IDs Template:OMIM5 Template:MGI HomoloGene600
RNA expression pattern
More reference expression data
Orthologs
Template:GNF Ortholog box
Species Human Mouse
Entrez n/a n/a
Ensembl n/a n/a
UniProt n/a n/a
RefSeq (mRNA) n/a n/a
RefSeq (protein) n/a n/a
Location (UCSC) n/a n/a
PubMed search n/a n/a

WikiDoc Resources for Granulocyte macrophage colony stimulating factor

Articles

Most recent articles on Granulocyte macrophage colony stimulating factor

Most cited articles on Granulocyte macrophage colony stimulating factor

Review articles on Granulocyte macrophage colony stimulating factor

Articles on Granulocyte macrophage colony stimulating factor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Granulocyte macrophage colony stimulating factor

Images of Granulocyte macrophage colony stimulating factor

Photos of Granulocyte macrophage colony stimulating factor

Podcasts & MP3s on Granulocyte macrophage colony stimulating factor

Videos on Granulocyte macrophage colony stimulating factor

Evidence Based Medicine

Cochrane Collaboration on Granulocyte macrophage colony stimulating factor

Bandolier on Granulocyte macrophage colony stimulating factor

TRIP on Granulocyte macrophage colony stimulating factor

Clinical Trials

Ongoing Trials on Granulocyte macrophage colony stimulating factor at Clinical Trials.gov

Trial results on Granulocyte macrophage colony stimulating factor

Clinical Trials on Granulocyte macrophage colony stimulating factor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Granulocyte macrophage colony stimulating factor

NICE Guidance on Granulocyte macrophage colony stimulating factor

NHS PRODIGY Guidance

FDA on Granulocyte macrophage colony stimulating factor

CDC on Granulocyte macrophage colony stimulating factor

Books

Books on Granulocyte macrophage colony stimulating factor

News

Granulocyte macrophage colony stimulating factor in the news

Be alerted to news on Granulocyte macrophage colony stimulating factor

News trends on Granulocyte macrophage colony stimulating factor

Commentary

Blogs on Granulocyte macrophage colony stimulating factor

Definitions

Definitions of Granulocyte macrophage colony stimulating factor

Patient Resources / Community

Patient resources on Granulocyte macrophage colony stimulating factor

Discussion groups on Granulocyte macrophage colony stimulating factor

Patient Handouts on Granulocyte macrophage colony stimulating factor

Directions to Hospitals Treating Granulocyte macrophage colony stimulating factor

Risk calculators and risk factors for Granulocyte macrophage colony stimulating factor

Healthcare Provider Resources

Symptoms of Granulocyte macrophage colony stimulating factor

Causes & Risk Factors for Granulocyte macrophage colony stimulating factor

Diagnostic studies for Granulocyte macrophage colony stimulating factor

Treatment of Granulocyte macrophage colony stimulating factor

Continuing Medical Education (CME)

CME Programs on Granulocyte macrophage colony stimulating factor

International

Granulocyte macrophage colony stimulating factor en Espanol

Granulocyte macrophage colony stimulating factor en Francais

Business

Granulocyte macrophage colony stimulating factor in the Marketplace

Patents on Granulocyte macrophage colony stimulating factor

Experimental / Informatics

List of terms related to Granulocyte macrophage colony stimulating factor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Overview

Granulocyte-macrophage colony-stimulating factor, often abbreviated to GM-CSF, is a protein secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts.

Functions

GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages. It is thus part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer.

Genetics

The gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. Other genes in the cluster include those encoding interleukins 4, 5, and 13.[1]

Glycosylation

Human granulocyte macrophage colony-stimulating factor is glycosylated in its mature form. The glycosylation sites are reported to be at amino acid residues 23 (leucine), 27 (asparagine), and 39 (glutamic acid) (see US Patent No. 5,073,627).[2]

Clinical significance

GM-CSF is also known as molgramostim or, when the protein is expressed in yeast cells, sargramostim (Leukine®).

GM-CSF is used as a medication to stimulate the production of white blood cells following chemotherapy. It has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising but GM-CSF is not presently FDA-approved for this purpose.

Leukine

Leukine is the trade name of sargramostim manufactured by Berlex Laboratories, a subsidiary of Schering AG. Its use was approved by U.S. Food and Drug Administration for acceleration of white blood cell recovery following autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease in March 1991.[3] In November 1996, the FDA also approved sargramostim for treatment of fungal infections and replenishment of white blood cells following chemotherapy.[4]

Controversy

Berlex funded a study that ran in the May 26 2005 issue of the New England Journal of Medicine which concluded that, GM-CSF did produce significantly more remissions in Crohn's disease than those who received a placebo in the study, and it also decreased disease severity and improved quality of life.[5]

The study's lead author, Joshua Korzenik of Harvard Medical School and Massachusetts General Hospital, is a paid consultant for Berlex , and co-inventor of the patent which is owned by Washington University.[6] Korzenik created a "firewall" to protect the integrity of the study, consisting of two committees to review the study results and process as well and sending trial data to outside clinicians for review.[6]

See also

References

  1. "Entrez Gene: CSF2 colony stimulating factor 2 (granulocyte-macrophage)".
  2. http://www.google.com/patents?vid=USPAT5073627&dq=5,073,627
  3. [1] Details of Approved Claims by Line of Therapy, Approved Claims for 1991, FDA.gov
  4. [2] Drugs Approved by the FDA, Drug Name: Leukine (sargramostim), CenterWatch.com
  5. Korzenik J, Dieckgraefe B, Valentine J, Hausman D, Gilbert M (2005). "Sargramostim for active Crohn's disease". N Engl J Med. 352 (21): 2193–201. PMID 15917384.
  6. 6.0 6.1 "Med school drug pushers: How scientists are selling out to drug companies", by David S. Bernstein, The Phoenix. Published April 12 2006. Accessed 8 Feb 2007.

Further reading

  • Esnault S, Malter JS (2002). "GM-CSF regulation in eosinophils". Arch. Immunol. Ther. Exp. (Warsz.). 50 (2): 121–30. PMID 12022701.
  • Martinez-Moczygemba M, Huston DP (2003). "Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF". J. Allergy Clin. Immunol. 112 (4): 653–65, quiz 666. doi:10.1016/S0091. PMID 14564341.
  • Mroczko B, Szmitkowski M (2005). "Hematopoietic cytokines as tumor markers". Clin. Chem. Lab. Med. 42 (12): 1347–54. doi:10.1515/CCLM.2004.253. PMID 15576295.
  • Hamilton JA, Anderson GP (2005). "GM-CSF Biology". Growth Factors. 22 (4): 225–31. doi:10.1080/08977190412331279881. PMID 15621725.
  • Tortorella C, Simone O, Piazzolla G; et al. (2007). "Age-related impairment of GM-CSF-induced signalling in neutrophils: role of SHP-1 and SOCS proteins". Ageing Res. Rev. 6 (2): 81–93. doi:10.1016/j.arr.2006.10.001. PMID 17142110.
  • Robertson SA (2007). "GM-CSF regulation of embryo development and pregnancy". Cytokine Growth Factor Rev. 18 (3–4): 287–98. doi:10.1016/j.cytogfr.2007.04.008. PMID 17512774.

External links

Template:WH Template:WikiDoc Sources